Updated Jul 16, 2026
Torti Frank has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $82.04M.
Frank Torti is the President and Vant Chair at Roivant Sciences Ltd., a biopharmaceutical company focused on improving healthcare delivery. He has been involved in the company's strategic direction and development of its drug candidates.
| Role | President and Vant Chair |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-02 | ROIV | Roivant Sciences Ltd. | F — Tax withholding / forfeiture | 40.3K | $35.39 | $1.43M |
| 2026-04-09 | IMVT | Immunovant, Inc. | A — Grant or award | 174.2K | $0.00 | |
| 2026-04-02 | ROIV | Roivant Sciences Ltd. | F — Tax withholding / forfeiture | 160.0K | $27.70 | $4.43M |
| 2026-02-24 | ROIV | Roivant Sciences Ltd. | S — Open-market sale [10b5-1] | 587.4K | $27.51 | $16.16M |
| 2026-02-24 | ROIV | Roivant Sciences Ltd. | M — Option exercise [10b5-1] | 587.4K | $3.85 | $2.26M |
| 2026-02-24 | ROIV | Roivant Sciences Ltd. | S — Open-market sale [10b5-1] | 1.01M | $27.15 | $27.49M |
| 2026-02-24 | ROIV | Roivant Sciences Ltd. | M — Option exercise [10b5-1] | 1.01M | $3.85 | $3.90M |
| 2026-02-24 | ROIV | Roivant Sciences Ltd. | S — Open-market sale [10b5-1] | 1.40M | $27.42 | $38.39M |
| 2026-02-24 | ROIV | Roivant Sciences Ltd. | M — Option exercise [10b5-1] | 1.40M | $3.85 | $5.39M |
| 2025-12-30 | ROIV | Roivant Sciences Ltd. | G — Bona-fide gift | 110.5K | $0.00 | |
| 2025-12-30 | ROIV | Roivant Sciences Ltd. | J — Other acquisition / disposition | 64.9K | $22.47 | $1.46M |
| 2025-12-30 | ROIV | Roivant Sciences Ltd. | A — Grant or award | 175.4K | $22.45 | $3.94M |
| 2025-07-30 | ROIV | Roivant Sciences Ltd. | A — Grant or award | 11.90M | $0.00 | |
| 2025-07-30 | ROIV | Roivant Sciences Ltd. | A — Grant or award | 1.84M | $0.00 |
Frank Torti is the President and Vant Chair at Roivant Sciences Ltd., a biopharmaceutical company focused on improving healthcare delivery. He has been involved in the company's strategic direction and development of its drug candidates.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($82.04M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Torti Frank profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.